GlassScriptPhysician profile
Adam Jeffrey Silver
NPI 1023423118
$8,185.03
in general payments reported to CMS, 2019-2025
27 companies · $1,592 in 2025
The $1,592 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.42 · 2020: $200 · 2021: $1,243 · 2022: $1,156 · 2023: $1,926 · 2024: $2,054 · 2025: $1,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,571.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,158.36 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,028.05 | 2021-2025 | Xarelto, Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $797.11 | 2020-2025 | Farxiga, Brilinta, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $786.08 | 2021-2025 | Jardiance |
| Amgen INC. | $773.33 | 2020-2025 | Repatha, Repatha |
| Novo Nordisk INC | $642.44 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $575.03 | 2020-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $543.26 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Boston Scientific Corporation | $351.19 | 2022-2025 | Watchman Flx, Watchman Access System |
| Medtronic, INC. | $314.92 | 2021-2025 | Linq II, Selectsecure, Corevalve Evolut R |
| Impulse Dynamics (USA) INC. | $175.94 | 2023 | Optimizer |
| Abiomed | $167.94 | 2023-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $118.22 | 2021-2022 | |
| Pfizer INC. | $117.17 | 2022-2025 | |
| Bridgebio Pharma, INC. | $102.68 | 2025 | Attruby |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $80.07 | 2022 | |
| Alnylam Pharmaceuticals INC. | $79.84 | 2024-2025 | Onpattro |
| Merck Sharp & Dohme LLC | $65.67 | 2024-2025 | Verquvo |
| Heartflow, INC. | $57.86 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $57.79 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $54.25 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $33.80 | 2024-2025 | Uptravi, Opsumit |
| Ionis Pharmaceuticals, INC. | $23.77 | 2025 | Tryngolza |
| Haemonetics Corporation | $23.07 | 2024 | Teg6s Hemostasis System |
| Lilly USA, LLC | $20.19 | 2024 | Zepbound, Jardiance |
| Edwards Lifesciences Corporation | $19.02 | 2021 | |
| Scpharmaceuticals INC. | $17.98 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.